EXCLUSIVE: Oragenics Tells Benzinga Co. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
Portfolio Pulse from Benzinga Newsdesk
Oragenics announced that its concussion drug, ONP-002, has successfully cleared FDA-required cardiotoxicity testing. This is a significant milestone for the company as it progresses in the development of this drug.
August 08, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oragenics' concussion drug, ONP-002, has successfully cleared FDA-required cardiotoxicity testing, marking a significant milestone in its development.
Clearing FDA-required cardiotoxicity testing is a critical step in drug development. This positive news is likely to boost investor confidence and positively impact Oragenics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100